Try a new search

Format these results:

Searched for:

person:tc907

in-biosketch:true

Total Results:

3


Bioprosthetic Aortic Valve Hemodynamics: Definitions, Outcomes, and Evidence Gaps: JACC State-of-the-Art Review

Herrmann, Howard C; Pibarot, Philippe; Wu, Changfu; Hahn, Rebecca T; Tang, Gilbert H L; Abbas, Amr E; Playford, David; Ruel, Marc; Jilaihawi, Hasan; Sathananthan, Janarthanan; Wood, David A; De Paulis, Ruggero; Bax, Jeroen J; Rodes-Cabau, Josep; Cameron, Duke E; Chen, Tiffany; Del Nido, Pedro J; Dweck, Marc R; Kaneko, Tsuyoshi; Latib, Azeem; Moat, Neil; Modine, Thomas; Popma, Jeffrey J; Raben, Jamie; Smith, Robert L; Tchetche, Didier; Thomas, Martyn R; Vincent, Flavien; Yoganathan, Ajit; Zuckerman, Bram; Mack, Michael J; Leon, Martin B
A virtual workshop was organized by the Heart Valve Collaboratory to identify areas of expert consensus, areas of disagreement, and evidence gaps related to bioprosthetic aortic valve hemodynamics. Impaired functional performance of bioprosthetic aortic valve replacement is associated with adverse patient outcomes; however, this assessment is complicated by the lack of standardization for labelling, definitions, and measurement techniques, both after surgical and transcatheter valve replacement. Echocardiography remains the standard assessment methodology because of its ease of performance, widespread availability, ability to do serial measurements over time, and correlation with outcomes. Management of a high gradient after replacement requires integration of the patient's clinical status, physical examination, and multimodality imaging in addition to shared patient decisions regarding treatment options. Future priorities that are underway include efforts to standardize prosthesis sizing and labelling for both surgical and transcatheter valves as well as trials to characterize the consequences of adverse hemodynamics.
PMID: 35902177
ISSN: 1558-3597
CID: 5276882

Characterization of initial/early histologic features of proliferative leukoplakia and correlation with malignant transformation: a multicenter study

Alabdulaaly, Lama; Villa, Alessandro; Chen, Tiffany; Kerr, Alexander; Ross, Nicholas; Abreu Alves, Fabio; Guollo, Andre; Woo, Sook-Bin
The aim of this multicenter retrospective study is to characterize the histopathologic features of initial/early biopsies of proliferative leukoplakia (PL; also known as proliferative verrucous leukoplakia), and to analyze the correlation between histopathologic features and malignant transformation (MT). Patients with a clinical diagnosis of PL who have at least one biopsy and one follow-up visit were included in this study. Initial/early biopsy specimens were reviewed. The biopsies were evaluated for the presence of squamous cell carcinoma (SCCa), oral epithelial dysplasia (OED), and atypical verrucous hyperplasia (AVH). Cases that lacked unequivocal features of dysplasia were termed "hyperkeratosis/parakeratosis not reactive (HkNR)". Pearson chi-square test and Wilcoxon test were used for statistical analysis. There were 86 early/initial biopsies from 59 patients; 74.6% were females. Most of the cases had a smooth/homogenous (34.8%) or fissured appearance (32.6%), and only 13.0% had a verrucous appearance. The most common biopsy site was the gingiva/alveolar mucosa (40.8%) and buccal mucosa (25.0%). The most common histologic diagnosis was OED (53.5%) followed by HkNR (31.4%). Of note, two-thirds of HkNR cases showed only hyperkeratosis and epithelial atrophy. A lymphocytic band was seen in 34.8% of OED cases and 29.6% of HkNR cases, mostly associated with epithelial atrophy. Twenty-eight patients (47.5%) developed carcinoma and 28.9% of early/initial biopsy sites underwent MT. The mortality rate was 11.9%. Our findings show that one-third of cases of PL do not show OED with most exhibiting hyperkeratosis and epithelial atrophy, but MT nevertheless occurred at such sites in 3.7% of cases.
PMID: 35184151
ISSN: 1530-0285
CID: 5167702

The deletion of Hdac4 in mouse osteoblasts influences both catabolic and anabolic effects in bone

Nakatani, Teruyo; Chen, Tiffany; Johnson, Joshua; Westendorf, Jennifer J; Partridge, Nicola C
Histone deacetylase 4 (Hdac4) is known to control chondrocyte hypertrophy and bone formation. We have previously shown that parathyroid hormone (PTH) regulates many aspects of Hdac4 function in osteoblastic cells in vitro; however, in vivo confirmation was previously precluded by pre-weaning lethality of the Hdac4 deficient mice. To analyze the function of Hdac4 in bone in mature animals, we generated mice with osteoblast lineage-specific knockout of Hdac4 (Hdac4ob-/-) by crossing transgenic mice expressing Cre recombinase under the control of a 2.3kb fragment of the Col1a1 promoter with mice bearing loxP-Hdac4. The Hdac4ob-/-mice survive to adulthood and developed a mild skeletal phenotype. At 12 weeks of age, they had short, irregularly-shaped and stiff tails due to smaller tail vertebrae, with almost no growth plates. The tibial growth plate zone was also thinned and Mmp13 and Sost mRNAs were increased in the distal femurs of Hdac4ob-/-mice. Immunohistochemistry showed that sclerostin was elevated in Hdac4ob-/-mice, suggesting that Hdac4 inhibits its gene and protein expression. To determine the effect of PTH in these mice, hPTH (1-34) or saline were delivered for 14 days with subcutaneously implanted devices in 8-week-old female Hdac4ob-/-and wild type (Hdac4fl/fl) mice. Serum CTX, a marker of bone resorption, was increased in Hdac4ob-/-mice with or without PTH treatment. Tibial cortical BV/TV, Ct.Th, and relative cortical area (RCA) were decreased in Hdac4ob-/-mice but PTH caused no further decrease in Hdac4ob-/-mice. Tibial trabecular BV/TV and thickness were not changed significantly in Hdac4ob-/-mice but decreased with PTH treatment. These results indicate that Hdac4 inhibits bone resorption and has anabolic effects via inhibiting Mmp13 and Sost/sclerostin expression. Hdac4 influences cortical bone mass and thickness and knockout of Hdac4 prevents the catabolic effect of PTH in cortical bone.
PMID: 29544022
ISSN: 1523-4681
CID: 2993032